
Bio-Rad Laboratories (BIO) Stock Forecast & Price Target
Bio-Rad Laboratories (BIO) Analyst Ratings
Bulls say
Bio-Rad Laboratories is attractive because its first organic growth quarter in 2026 showed early recovery, with revenue up 0.7%, led by Clinical Diagnostics at +2.8% and improving Life Science ex-process chromatography growth of about 2.5%. Management’s restructuring and R&D rationalization, including a 17% reduction in R&D headcount and $30–$35 million of net annualized cost savings, support margin expansion toward FY26 gross margin guidance of 53%–54% and operating margin of 10%–12%. The stock also benefits from optionality in its ~33% Sartorius stake, while valuation remains reasonable at about 14x–15x EV/EBITDA versus a higher peer multiple, leaving room for rerating as headwinds fade in 2027 and beyond.
Bears say
Bio-Rad Laboratories is facing a negative outlook because investors may continue to lose confidence in its sales and margin trajectory, driving further multiple erosion and a steeper discount on its Sartorius stake, which could depress valuation under a 15x EBITDA framework. The company also faces prolonged end-market weakness in life science tools, ongoing share losses in ddPCR to Qiagen, and mixed M&A execution, all of which point to weaker organic growth and integration risk. In addition, its life science exposure to wet-lab research creates structural pressure if software and AI reduce demand, while the dual-class share structure and Schwartz family control raise governance concerns that may limit shareholder alignment.
This aggregate rating is based on analysts' research of Bio-Rad Laboratories and is not a guaranteed prediction by Public.com or investment advice.
Bio-Rad Laboratories (BIO) Analyst Forecast & Price Prediction
Start investing in Bio-Rad Laboratories (BIO)
Order type
Buy in
Order amount
Est. shares
0 shares
FAQs About Bio-Rad Laboratories (BIO) Forecast
Bio-Rad Laboratories (BIO) Analyst Forecast & Price Prediction
Start investing in Bio-Rad Laboratories (BIO)
Order type
Buy in
Order amount
Est. shares
0 shares